Owkin believes that medical research should be collaborative, inclusive, and privacy-preserving. Today, Owkin is pioneering AI in healthcare. It leverages its collaborative federated learning software and expert AI capabilities to bring solutions to optimize drug development and improve patient care in oncology. Owkin’s work has been published in Nature Medicine and other top-tier journals. Owkin has raised over $70M from leading VC funds and is now working with the most prominent cancer centers and pharmaceutical companies in Europe and the US. Additionally, Owkin leads several federated learning consortia, including; MELLODDY, to facilitate 'co-opetive' drug discovery between pharma companies, and Healthchain, to allow collaborative research across multiple hospitals. Owkin was co-founded in 2016 by Thomas Clozel, MD, a clinical research doctor and former assistant professor in clinical hematology, and by Gilles Wainrib, Ph.D., an academic pioneer in the field of Artificial Intelligence in biology.

Biotechnology

Owkin

Thomas Clozel

Andrew Pierce

Amelie Ravasé

Elodie Pronier

Caroline Hoffmann

Sonia Grouchko

Greg Taylor

Lionel Guillou

Antonia Trower

Anne-Charlotte Paut

Rodrigo Barnes

Agathe Arlotti

Michaël Auffret

Eric Durand

Leo Cunningham

David Cahané

Jean-Philippe Vert

Ablan De La Sablière

Mariabrisa Olivares

Hubert Chaperon

Meriem Sefta

Darius Meadon

Vassili Soumelis

Jean-Frédéric Petit-Nivard

Yedidia Levy-Zauberman

Senior Solutions Architect

Machine Learning Engineer

Data Portfolio Analyst

Leadership Team

Chief Officers

Heads and SVPs

Scientific Advisory Team

Directorship Team

Product and Technology

Teams at Owkin